吉西他滨膀胱灌注预防非肌层浸润膀胱癌术后复发的疗效观察  

Curative efficacy of intravesical reperfusion with gemcitabine for preventing postoperative recurrence of non-muscle invasive bladder cancer

作　　者：刘小勇[1] 向宸辉[1] 陈胜龙[1] LIU Xiao-yong;XIANG Chen-hui;CHEN Sheng-long(Department of Urology,The First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,China)

机构地区：[1]成都医学院第一附属医院泌尿外科,四川成都610500

出　　处：《实用医院临床杂志》2018年第1期148-150,共3页Practical Journal of Clinical Medicine

摘　　要：目的探讨吉西他滨膀胱灌注预防非肌层浸润膀胱癌(NMIBC)经尿道切除(TURBT)术后复发的临床疗效。方法 126例NMIBC术后患者按随机数字表法分为观察组和对照组各63例。观察组TURBT术后即刻予吉西他滨膀胱灌注,对照组TURBT术后即刻予吡柔比星膀胱灌注,随访2年。观察两组随访期间肿瘤复发率、首次复发时间、肿瘤进展率、进展时间和不良反应发生情况。结果观察组肿瘤复发率低于对照组,肿瘤复发时间长于对照组(P<0.05)。两组肿瘤进展率、进展时间差异均无统计学意义(P>0.05)。观察组不良反应总发生率低于对照组(P<0.05)。结论吉西他滨膀胱灌注化疗预防非肌层浸润性膀胱癌TURBT术后肿瘤复发具有较好疗效,且不良反应发生率低。To observe the clinical effect of intravesical reperfusion with gemcitabine for preventing postoperative recurrence of non-muscle invasive bladder cancer(NMIBC)after transurethral bladder tumor resection(TURBT).One hundred and twenty-six patients with NMIBC after TURBT were randomly divided into control group and observation group,63 in each group.The observation group and control group received intravesical perfusion with gemcitabine and pirarubicin after TURBT,respectively.The 2-year tumor recurrence rate,time of first recurrence,rate and time of tumor progression and adverse reactions of chemotherapy were compared between the two groups.The 2-year tumor recurrence rate and the mean time of first recurrence of observation group was lower and longer than that of the control group(P<0.05).There were no statistical difference in the time and rate of tumor recurrence progression between the two groups(P>0.05).The total rates of adverse reactions in the observation group were lower than that in the control group(P<0.05).The therapeutic of intravesical perfusion with gemcitabine is effective to prevent postoperative recurrence in patients with NMIBC and has light adverse reactions.

关 键 词：吉西他滨 膀胱灌注 膀胱癌 复发 

分 类 号：R737.14[医药卫生—肿瘤]